A comprehensive safety study on the JAK inhibitor tofacitinib, used for rheumatoid arthritis, revealed concerning risks compared to tumor necrosis factor inhibitors. These risks include major cardiovascular issues, various cancers (particularly lung, lymphomas, and non-melanoma skin cancers), severe infections, and increased mortality
Continue reading →